frisko6@yahoo.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
looks like 399 is the next resistance
she's stacken
Nice open, up in the 36 range, looking at 37, heavy Vol,
WOW, what an ending, watched it on Schwab 3548
Live ticker AMAZING,
Its got the momentum, thats for sure
Not so big,, New Jersey local, Bergen County news
It should hit the papers BIG NEWS, READ ALL ABOUT IT
could get a lot of clicks
3 million traded, looking good, holding her own at 34, lets see if she closes at 355 high of day
For sure jour, I don't think we are on the same page, I think the bottom line last Q was plus 4 mill, when it should have been plus 14 mill, because they spent 10 mill on new equipment for the new plant
Also Cake, They spent a lot of money the first quarter buying equipment for the new facility, and getting it ready,
that expense is done,
should see it reflected in the next financials.
that is ,
on the bottom line
7 million shares for the day, one tic below 34cents,
Looking forward to tomorrow, another big day.
Were back to number one most read.
Everbody, behave your selves….
Look sharp, cross your tees and dot those eyes.
Another feather in Nasrats hat, even if we don’t get first to file, it’s still a huge market.
Double WOW
Fantastic.
WOW, THX, I had all but given up.
You get a pass, pretty exciting times, I can barely type too, have to do spell CK a lot
Don't forget the two opioids to be launched 4 weeks apart
Tylenol and Percocet
40 cents by Fri. hmm, it could happen, nobody is selling ,Biggly, if they want in this thing they gotta ask
Spoke to soon, make that 349,
IN NASRAT WE TRUST
Looks like 339 is the new resistance
Who ever sold , is now chassing
I’m getten dizzy
Nice open, we could see 35. On a mini pop
Looks like were just going to have to put the Purdue/Accord lawsuit
On the back back back burner on low low heat til Feb.3/25
https://www.pacermonitor.com/public/case/53616923/Purdue_Pharma_LP_et_al_v_Accord_Healthcare_Inc
Well Bubba, we all know it's obvious, his posts are for the newbies, and anybody researching Elite over the weekend,
good stuff.
we should see another mini pop tomorrow
CNBC has a PE of 16.39, the same as Schwab
https://www.cnbc.com/quotes/ELTP?qfsearchterm=eltp
Would be nice, but they have to talk about the intangibles , not just the numbers
Another reason I say Elite will sell every pill they can make
https://finance.yahoo.com/news/why-big-pharma-is-betting-on-telehealth-strategies-205258463.html
Enter Kirko, stage left
Is Elite Pharmaceuticals Ready For A Breakout? New Product Launches Could Fuel Growth
WTS Capital
August 24, 2024
From an article last month
Elite Pharmaceuticals (OTC: ELTP) is a specialty drug company focusing on developing and manufacturing generic medications, with a strong presence in controlled-release and abuse-deterrent formulations. They produce generics for well-known drugs like Adderall, Naltrexone, and Phentermine. Recently, Elite has concentrated on expanding its pipeline to include high-demand opioids and central nervous system medications.
The company operates out of New Jersey, and while it may not be a household name, Elite has steadily built a solid foundation in the generics market. Their focus on niche areas, including opioids, where they employ technologies designed to reduce abuse, has set them apart from other players in the space.
Why We Like The Stock
Elite Pharmaceuticals is on a promising growth trajectory. In the past few years, the company has ramped up its revenues, from $7.5 million in 2019 to over $56 million by 2024. The first quarter of fiscal year 2025 was no exception to this trend, with the company generating $18.8 million in revenue, more than double what it made in the same period the year before.
A key driver of this growth is the company’s planned product launches. Elite has lined up several generic drugs for release over the next few months, including methadone, oxycodone/acetaminophen (Percocet), and hydrocodone/acetaminophen (Norco). These drugs, collectively worth over $1 billion in market value, could significantly boost Elite’s revenues. Even with modest market penetration, these new products have the potential to double the company’s revenue in the near term.
Adding to this is Elite’s new manufacturing facility, which is expected to increase production capacity by 400% once it receives FDA approval. That approval is anticipated by November 2024, positioning Elite to meet the growing demand for its products. With a stronger production capacity and new generics hitting the market, the company seems well-positioned for continued revenue growth.
One of the more interesting pieces of Elite's pipeline is an ADHD drug awaiting FDA approval, which could open the door to a much larger market for the company. This CNS drug has a market value of $5.1 billion, and if Elite can secure even a small slice of that market, it could see a major boost in revenue.
Is Elite Pharmaceuticals Ready For A Breakout? New Product Launches Could Fuel Growth
WTS Capital
August 24, 2024
Elite Pharmaceuticals (OTC: ELTP) is a specialty drug company focusing on developing and manufacturing generic medications, with a strong presence in controlled-release and abuse-deterrent formulations. They produce generics for well-known drugs like Adderall, Naltrexone, and Phentermine. Recently, Elite has concentrated on expanding its pipeline to include high-demand opioids and central nervous system medications.
The company operates out of New Jersey, and while it may not be a household name, Elite has steadily built a solid foundation in the generics market. Their focus on niche areas, including opioids, where they employ technologies designed to reduce abuse, has set them apart from other players in the space.
Why We Like The Stock
Elite Pharmaceuticals is on a promising growth trajectory. In the past few years, the company has ramped up its revenues, from $7.5 million in 2019 to over $56 million by 2024. The first quarter of fiscal year 2025 was no exception to this trend, with the company generating $18.8 million in revenue, more than double what it made in the same period the year before.
A key driver of this growth is the company’s planned product launches. Elite has lined up several generic drugs for release over the next few months, including methadone, oxycodone/acetaminophen (Percocet), and hydrocodone/acetaminophen (Norco). These drugs, collectively worth over $1 billion in market value, could significantly boost Elite’s revenues. Even with modest market penetration, these new products have the potential to double the company’s revenue in the near term.
Adding to this is Elite’s new manufacturing facility, which is expected to increase production capacity by 400% once it receives FDA approval. That approval is anticipated by November 2024, positioning Elite to meet the growing demand for its products. With a stronger production capacity and new generics hitting the market, the company seems well-positioned for continued revenue growth.
One of the more interesting pieces of Elite's pipeline is an ADHD drug awaiting FDA approval, which could open the door to a much larger market for the company. This CNS drug has a market value of $5.1 billion, and if Elite can secure even a small slice of that market, it could see a major boost in revenue.
Risks & Considerations
WHOA, looks like 32.9 is the next resistance
she made a GAP
look out
32. YEAH
looks like 31.9 is the next resistance , it could hit 32 EOD
YES, Rich, and everyone selling out of the blue chips with tons of cash in their banks with money to spend are looking for
the next big thing
enter Elite
Good job, you get a gold star
No prob Bubba
THIRTY CENTS, I think that was before lunch
lost track of time, lol
YES, that's why Nasrat was surprised about Nov. , Elite got put on the fast track, with the new building and Vyvanse
I'm perklempt
discuss
ps. I hate Bloomberg, they won't let me read with out a subscription.
but word is getting out, lots of eyes on this one
Last paragraph from yesterday's article
“Extrapolation utilizing previous years’ reported data suggests the export requirements for lisdexamfetamine active pharmaceutical ingredient and finished dosages likely will continue to increase in 2024 and beyond,” the DEA said. “An increase in domestic manufacturing of the active pharmaceutical ingredient and finished dosages is necessary to supply lisdexamfetamine products to foreign markets.”
Do I see FOREIGN MARKETS, wow, sounds like they will let Elite go global,
Enter Mr. Kirko, again